Related Experiment Video
Updated: May 15, 2026

Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic
Flora McErlane1, Michael W Beresford, Eileen M Baildam
1Arthritis Research UK Epidemiology Unit, University of Manchester, , Manchester, UK.
Insights
Excluding erythrocyte sedimentation rate (ESR) from the Juvenile Arthritis Disease Activity Score (JADAS) improved its clinical applicability for most juvenile idiopathic arthritis (JIA) categories. The modified JADAS (JADAS3) showed excellent correlation with the original JADAS, supporting its use in routine clinical settings.
Area of Science:
- Pediatric Rheumatology
- Clinical Trial Methodology
- Disease Activity Measurement
Background:
- The Juvenile Arthritis Disease Activity Score (JADAS) is a key tool for assessing disease activity in juvenile idiopathic arthritis (JIA).
- Its validity and feasibility across all JIA categories in routine clinical practice require further investigation.
- The impact of excluding the erythrocyte sedimentation rate (ESR) on JADAS's correlation with disease markers is not fully understood.
Purpose of the Study:
- To evaluate the validity and feasibility of JADAS in all JIA categories within a routine UK clinical setting.
- To determine if excluding ESR (creating JADAS3) affects JADAS's correlation with single disease activity markers.
Main Methods:
- JADAS and JADAS3 scores (versions 71, 27, and 10) were calculated at baseline for an inception cohort of children with JIA.
- Correlation analyses were performed between JADAS, JADAS3, and individual disease activity/severity measures, stratified by JIA category.
Main Results:
- JADAS and JADAS3 data were available for 352 and 551 children, respectively.
- JADAS and JADAS3 scores varied significantly across JIA categories, with highest values in polyarticular disease patterns.
- Excellent correlation was observed between JADAS and JADAS3 across all categories.
- JADAS3-71 showed similar correlations to JADAS-71 with most indices, except ESR.
Conclusions:
- This study provides evidence for the feasibility and construct validity of JADAS across all JIA categories in a UK routine clinical setting.
- Excluding ESR from JADAS (JADAS3) appears to enhance its clinical applicability for most JIA categories.
- JADAS3 demonstrates strong potential as a valid and practical measure of disease activity in JIA.
Objectives:
To investigate the validity and feasibility of the Juvenile Arthritis Disease Activity Score (JADAS) in the routine clinical setting for all juvenile idiopathic arthritis (JIA) disease categories and explore whether exclusion of the erythrocyte sedimentation rate (ESR) from JADAS (the 'JADAS3') influences correlation with single markers of disease activity.
Methods:
JADAS-71, JADAS-27 and JADAS-10 were determined at baseline for an inception cohort of children with JIA in the Childhood Arthritis Prospective Study. JADAS3-71, JADAS3-27 and JADAS3-10 were determined using an identical formula but with exclusion of ESR. Correlation of JADAS with JADAS3 and single measures of disease activity/severity were determined by category.
Results:
Of 956 eligible children, sufficient data were available to calculate JADAS-71, JADAS-27 and JADAS-10 at baseline in 352 (37%) and JADAS3 in 551 (58%). The median (IQR) JADAS-71, JADAS-27 and JADAS-10 for all 352 children was 11 (5.9-18), 10.4 (5.7-17) and 11 (5.9-17.3), respectively. Median JADAS and JADAS3 varied significantly with the category (Kruskal-Wallis p=0.0001), with the highest values in children with polyarticular disease patterns. Correlation of JADAS and JADAS3 across all categories was excellent. Correlation of JADAS71 with single markers of disease activity/severity was good to moderate, with some variation across the categories. With the exception of ESR, correlation of JADAS3-71 was similar to correlation of JADAS-71 with the same indices.
Conclusions:
This study is the first to apply JADAS to all categories of JIA in a routine clinical setting in the UK, adding further information about the feasibility and construct validity of JADAS. For the majority of categories, clinical applicability would be improved by exclusion of the ESR.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Asthma-III: Symptoms and Complications
Classification of Asthma
Inflammatory Bowel Disease III: Crohn's Disease
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Rheumatic Heart Disease III: Medical Management
Asthma III: Clinical Manifestations
